SCTC21C
/ Sinocelltech
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
February 06, 2026
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
(clinicaltrials.gov)
- P3 | N=90 | Recruiting | Sponsor: Sinocelltech Ltd.
New P3 trial • Amyloidosis
January 30, 2026
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
(clinicaltrials.gov)
- P3 | N=292 | Recruiting | Sponsor: Sinocelltech Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation
December 23, 2025
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
(clinicaltrials.gov)
- P3 | N=292 | Not yet recruiting | Sponsor: Sinocelltech Ltd.
New P3 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation
January 14, 2025
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
(clinicaltrials.gov)
- P1/2 | N=99 | Not yet recruiting | Sponsor: Sinocelltech Ltd.
New P1/2 trial • Glomerulonephritis • IgA Nephropathy • Immunology • Renal Disease
April 22, 2024
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=74 | Recruiting | Sponsor: Sinocelltech Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Disorders • Hematological Malignancies • Oncology
February 09, 2024
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=74 | Not yet recruiting | Sponsor: Sinocelltech Ltd.
New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology
1 to 6
Of
6
Go to page
1